8640 Stock Overview
Operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lixte Biotechnology Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.22 |
| 52 Week High | US$6.54 |
| 52 Week Low | US$1.73 |
| Beta | -0.23 |
| 1 Month Change | -29.30% |
| 3 Month Change | 1.83% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8640 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | -0.5% |
| 1Y | n/a | -24.7% | 5.2% |
Return vs Industry: Insufficient data to determine how 8640 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 8640 performed against the German Market.
Price Volatility
| 8640 volatility | |
|---|---|
| 8640 Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8640's share price has been volatile over the past 3 months.
Volatility Over Time: 8640's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4 | Bas van der Baan | lixte.com |
Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases. The company primarily focuses on inhibitors of protein phosphatase 2A that are used in combination with cytotoxic agents and/or x-ray, immune checkpoint blockers and other cancer therapies. It develops LB-100 that has completed phase I clinical trial for advanced soft tissue carcinoma and small cell lung cancer, as well as is in Phase II clinical trial for ovarian clear cell cancer.
Lixte Biotechnology Holdings, Inc. Fundamentals Summary
| 8640 fundamental statistics | |
|---|---|
| Market cap | €5.04m |
| Earnings (TTM) | -€4.32m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 8640 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8640 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.69m |
| Earnings | -US$4.69m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 8640 perform over the long term?
See historical performance and comparison